CIMT 2010: Report on the eighth annual meeting of the association for cancer immunotherapy, May 26–28, 2010, Mainz, Germany
- 74 Downloads
In 2010, the first therapeutic vaccine against cancer received approval of the Food and Drug Administration (FDA) in USA. In addition, several reports from randomized phase III trials showing improved survival in cancer patients receiving immunotherapy raised great hopes for the field of cancer immunotherapy. These recent reports formed the central topic in many discussions among participants of the Association for Cancer Immunotherapy Meeting (CIMT) 2010, who had been longing for major tangible breakthroughs in clinical immunotherapy development for several years. With the number of attendants gradually increasing to above 450 international participants, the series of annual CIMT meetings has definitively placed itself as one of the top European meetings focussing on immunology and cancer. This is also reflected by the increasing number of industrial exhibitors, three well-visited satellite workshops and over 120 submitted abstracts from which 25 were selected for oral presentations,...